Fig. 4

RNAseq immune cell differences in patient biopsies. A-B CIBESORTx characterization of the immune infiltrate obtained from RNAseq analyses performed on fresh frozen tumor samples in patients with stable disease, partial or complete response (SD/PR/CR) (A) and in patients who progressed (PD) (B), according to the treatment timepoint (baseline, week 3 and week 7). For each analyzed tumor sample, a bar chart depicts the absolute score of each immune subpopulation and is accompagned with a circular representation that indicates the relative fraction of granulocytes, monocytes/macrophages and lymphocytes within the sample, as indicated. Yellow and red stars refer respectivelly to MSI-high patients and elite responders (> 1 year). C-E. Scatter dot plots comparating the total CIBESORTx score found in patients with SD/PR/CR versus patients who progressed in tumor samples collected at baseline (C), at week 3 (D) and at week 7 (E). Mean with SD are represented. ns > 0.05; 0.01 ≤ ** < 0.001